Can You Crush Biktarvy?
No, crushing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is not recommended. 1
Guideline Recommendation
The 2020 International Antiviral Society-USA Panel explicitly states: "Crushing bictegravir/tenofovir alafenamide/emtricitabine is not recommended" 1. This recommendation appears in the context of managing patients with chemotherapy-induced severe mucositis who need alternative formulations, indicating that even in situations where crushing would be clinically convenient, it should be avoided.
Why Crushing Is Problematic
Pharmacokinetic Evidence
The highest quality study addressing this question is a 2022 randomized crossover trial in healthy adults 2, which demonstrated:
- Crushed tablets resulted in suboptimal drug exposures:
- Emtricitabine Cmax: only 70% of reference (90% CI: 63-78%)
- Tenofovir alafenamide Cmax: only 66% of reference (90% CI: 51-85%)
- Emtricitabine AUC: 86% of reference (90% CI: 82-91%)
- Tenofovir alafenamide AUC: 84% of reference (90% CI: 69-103%)
These exposures fell outside the 80-125% bioequivalence range required for therapeutic equivalence, meaning crushed tablets deliver inadequate drug levels.
Clinical Failure Case
A 2022 case report documented virologic failure when crushed Biktarvy was administered via PEG tube 3:
- Patient's viral load increased from 5,887 to 8,047 copies/mL despite 37 consecutive doses of crushed Biktarvy
- Minor resistance mutations (E157Q and V118I) developed
- Required regimen change to achieve viral suppression
This real-world failure confirms that crushing compromises antiviral efficacy and can lead to resistance development.
Alternative: Dissolving in Water
If a patient cannot swallow tablets whole, dissolving Biktarvy in water is a more acceptable alternative 2:
- Dissolved tablets maintained bioequivalence for all three components:
- Bictegravir: 111% AUC (90% CI: 100-122%)
- Emtricitabine: 100% AUC (90% CI: 94-105%)
- Tenofovir alafenamide: 99% AUC (90% CI: 81-120%)
However, this remains off-label and should only be used when absolutely necessary.
Practical Considerations for Dissolving
- One pediatric case report showed successful viral suppression with dissolved low-dose Biktarvy 4
- A hospital study found 89% (17/19) of patients achieved viral suppression within 1 year when receiving dissolved or crushed Biktarvy via enteral tube 5, though this mixed crushing and dissolving methods
Clinical Algorithm
When a patient cannot swallow Biktarvy tablets:
First choice: Split the tablet and have the patient take each part separately within 10 minutes (this is FDA-approved for children) 6
Second choice: Dissolve the tablet in water and administer immediately (off-label but pharmacokinetically acceptable) 2
Third choice: Switch to an alternative antiretroviral regimen that has a liquid formulation or can be safely crushed (e.g., raltegravir, dolutegravir) 1
Avoid: Crushing Biktarvy and mixing with food or administering via tube, as this leads to suboptimal drug levels and potential treatment failure 2, 3
Critical Pitfalls
- Do not assume crushing is acceptable just because some observational data show partial success—the controlled pharmacokinetic study clearly demonstrates inadequate drug exposure 2
- Monitor viral load closely (at 4 weeks) if dissolving tablets, as this is off-label use
- Consider drug interactions with tube feeds if administering via enteral tube, as these may further reduce absorption
- Resistance testing is essential if viral load increases on any modified formulation